Patents Represented by Attorney Jane Massey Licata

Find this attorney in the Justia Lawyer Directory

  • Antisense modulation of inhibitor-kappa B kinase-beta expression
    Patent number: 5977341
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-beta. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-beta expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-beta are provided.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: November 2, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of integrin .alpha.4 expression
    Patent number: 5968826
    Abstract: Compositions and methods are provided for modulating the expression of integrin .alpha.4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin .alpha.4 are preferred. Methods of using these compounds for modulating integrin .alpha.4 expression and for treatment of diseases associated with expression of integrin .alpha.4 are also provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: October 19, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Lex M. Cowsert
  • Antisense modulation of RhoG expression
    Patent number: 5965370
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoG. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoG. Methods of using these compounds for modulation of RhoG expression and for treatment of diseases associated with expression of RhoG are provided.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: October 12, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense modulation of inhibitor-kappa B kinase-alpha expression
    Patent number: 5962673
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-alpha. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-alpha expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-alpha are provided.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: October 5, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of fan expression
    Patent number: 5962671
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of FAN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FAN. Methods of using these compounds for modulation of FAN expression and for treatment of diseases associated with expression of FAN are provided.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: October 5, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Antisense modulation of RhoB expression
    Patent number: 5962672
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoB. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoB. Methods of using these compounds for modulation of RhoB expression and for treatment of diseases associated with expression of RhoB are provided.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: October 5, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Coswert
  • Bowman-birk inhibitor compositions and methods for the treatment of genitourinary diseases
    Patent number: 5961980
    Abstract: A composition containing a Bowman Birk Inhibitor and a pharmaceutically acceptable carrier are provided for treatment of genitourinary tract diseases relating to smooth muscle contraction leading to urinary symptoms and male sexual dysfunction or atypical prostate cells. Methods of using these compositions in treatment of these diseases are also provided.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: October 5, 1999
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ann R. Kennedy, Larry Clark
  • Characterization of mRNA patterns in neurites and single cells for medical diagnosis and therapeutics
    Patent number: 5958688
    Abstract: A method of identifying neurite cDNA clones by determining and comparing mRNA expression in selected neurites is provided. cDNA clones identified by this method are also provided. In addition, methods of profiling mRNA expression and diagnosing and treating conditions associated with a pattern of mRNA expression by determining an mRNA expression profile in selected cells are provided.
    Type: Grant
    Filed: April 28, 1997
    Date of Patent: September 28, 1999
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James Eberwine, Marc Dichter, Kevin Miyashiro
  • Antisense modulation of AKT-1 expression
    Patent number: 5958773
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-1. Methods of using these compounds for modulation of Akt-1 expression and for treatment of diseases associated with expression of Akt-1 are provided.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: September 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of cellular inhibitor of apoptosis-1 expression
    Patent number: 5958772
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-1. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-1 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-1 are provided.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: September 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Lex M. Cowsert
  • Antisense modulation of cellular inhibitor of Apoptosis-2 expression
    Patent number: 5958771
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-2. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-2 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-2 are provided.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: September 28, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Lex M. Cowsert
  • Antisense modulation of MEK2 expression
    Patent number: 5959097
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEK2. Methods of using these compounds for modulation of MEK2 expression and for treatment of diseases associated with expression of MEK2 are provided.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: September 28, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of PECAM-1
    Patent number: 5955443
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a platelet endothelial cell adhesion molecule-1 (PECAM-1; also known as CD31 antigen or endoCAM) protein are provided.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: September 21, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy, Hong Zhang
  • Antisense modulation of G-alpha-11 expression
    Patent number: 5951455
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-11. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-11. Methods of using these compounds for modulation of G-alpha-1l expression and for treatment of diseases associated with expression of G-alpha-11 are provided.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: September 14, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Lex M. Cowsert
  • Antisense oligonucleotide modulation of raf gene expression
    Patent number: 5952229
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. In preferred embodiments, the oligonucleotides are targeted to mRNA encoding human c-raf or human A-raf. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: September 14, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Russell T. Boggs
  • Antisense inhibition of Elk-1 expression
    Patent number: 5948680
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ELK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ELK-1. Methods of using these compounds for modulation of ELK-1 expression and for treatment of diseases associated with expression of ELK-1 are provided.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: September 7, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Method of nanoscale patterning and products made thereby
    Patent number: 5948470
    Abstract: Methods of nanometer pattern formation and transfer onto a selected substrate are provided wherein a selected block copolymer is coated onto the selected substrate and a component of the block copolymer is chemically modified or physically removed so that the dense periodic pattern of the block copolymer can be transferred onto the selected substrate. Substrates prepared by these methods are also provided.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: September 7, 1999
    Inventors: Christopher Harrison, Miri Park, Richard Register, Douglas Adamson, Paul Mansky, Paul Chaikin
  • Antisense modulation of RhoA expression
    Patent number: 5945290
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoA. Methods of using these compounds for modulation of RhoA expression and for treatment of diseases associated with expression of RhoA are provided.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: August 31, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Lex M. Cowsert
  • Compositions and methods for weight reduction
    Patent number: 5945107
    Abstract: Compositions containing a combination of selected herbal plant extracts that inhibit gastric emptying time and increase metabolic rate are provided which are useful in reducing weight in patients.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: August 31, 1999
    Assignee: Natural Medio Tech A/S
    Inventors: Lasse Lief Hessel, Jorgen Scherning Lundsgaard
  • Method of detecting and treating cancer
    Patent number: 5942402
    Abstract: The present invention provides a new method for diagnosing and treating cancers or BPH. Further provided are therapeutic agents and pharmaceutical compositions for treating cancers and BPH.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: August 24, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Carl J. Schmidt, Frank Tobin, Francis E. Wilkinson